The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation

On October 24, 2019, a marketing authorization valid through the European Union (EU) was issued for gilteritinib monotherapy for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an Fms‐like tyrosine kinase 3 (FLT3) mutation. Gilteritinib inhibits FLT3 receptor signali...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Tzogani, Kyriaki, Røshol, Hilde, Olsen, Helga Haugom, Aas, Ida B., Dalhus, Marianne Løiten, Håkonsen, Gro Dahlseng, Nilssen, Laila Sortvik, Lindberg, Vibeke, Økvist, Mats, Bolstad, Bjørg, Rogovska, Irēna, Karpova, Natalja, Enzmann, Harald, Gisselbrecht, Christian, Pignatti, Francesco
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2020
Matèries:
Regulatory Issues: EMA
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7356782/
https://ncbi.nlm.nih.gov/pubmed/32154636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0976
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars